Cadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor Conference

PONTE VEDRA, Fla., Feb. 6, 2023 — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today announced that Chairman and Chief Executive Officer, Quang Pham, is available for one-on-one meetings at the BIO CEO & Investor Conference taking place […]

Cadrenal Therapeutics Announces Formation of Scientific Advisory Board

PONTE VEDRA, Fla., Feb. 1, 2023 — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, announced today the formation of its Scientific Advisory Board (SAB) in support of the development of tecarfarin for the prevention of systemic thromboembolism, more […]

Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering

Cadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering PONTE VEDRA, Fla., Jan. 24, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the closing of its initial public offering of 1,400,000 shares of common stock at a public offering price […]

Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation

Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation PONTE VEDRA, Florida – January 23, 2023 – Cadrenal Therapeutics, Inc., a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation, announced […]

Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO)

Cadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO) PONTE VEDRA, Florida – January 20, 2023 – Cadrenal Therapeutics, Inc., a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation, announced today the pricing of its initial public offering of 1,400,000 shares of common stock at a public offering price […]

Cadrenal Therapeutics Announces Appointment of Douglas Losordo, MD as Chief Medical Officer

Cadrenal Therapeutics Announces Appointment of Douglas Losordo, MD as Chief Medical Officer PONTE VEDRA, Florida – July 25, 2022 –Cadrenal Therapeutics, Inc. (“Cadrenal”), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the appointment of Douglas W. Losordo, MD, FACC, FAHA as Chief Medical Officer. Quang […]

Cadrenal Therapeutics Announces Confidential Submission of Draft Registration Statement Related to Proposed Public Offering

Cadrenal Therapeutics Announces Confidential Submission of Draft Registration Statement Related to Proposed Public Offering   PONTE VEDRA, Florida – July 15, 2022 – Cadrenal Therapeutics, Inc. (“Cadrenal”), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, announced today that it has confidentially submitted a draft registration statement on […]

Cadrenal Therapeutics Appoints Matthew K. Szot as Chief Financial Officer

Cadrenal Therapeutics Appoints Matthew K. Szot as Chief Financial Officer  PONTE VEDRA, Florida – May 17, 2022 –Cadrenal Therapeutics, Inc. (“Cadrenal”), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug indication, today announced the appointment of Matthew K. Szot as the Company’s Chief Financial Officer (“CFO”). Szot brings more […]

Cadrenal Therapeutics Acquires Tecarfarin from Horizon

Cadrenal Therapeutics Acquires Tecarfarin from Horizon PONTE VEDRA, Florida – April 1, 2022 – Cadrenal Therapeutics, Inc. (“Cadrenal”) has acquired the rights to tecarfarin from Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, […]